In other cancer mouse models, sirt1 can protect against the development of intestinal tumors in a β-catenin-driven colon cancer model [147], sarcomas, lymphomas, teratomas, and carcinomas arising from deletion of p53 [148], HFD-induced hepatocarcinomas [116], and age-associated spontaneous tumor development [116]. Here, TP53 is linked to lymphoma.